Vial Sharing of High-Cost Drugs to Decrease Leftovers and Costs: A Retrospective Observational Study on Patisiran Administration in Bologna, Italy
Waste of high-cost medicines, such as orphan drugs, is a major problem in healthcare, which leads to excessive costs for treatments. The main objective of this study was to evaluate the impact of a vial-sharing strategy for patisiran, an orphan drug used for the treatment of hereditary transthyretin...
Main Authors: | Margherita Cozzio, Alessandro Melis, Giusy La Fauci, Pietro Guaraldi, Rosaria Caputo, Flavia Lioi, Giulia Sangiorgi Cellini, Giuseppina Santilli, Donatella Scarlattei, Pasquale Siravo, Paola Zuccheri, Andrea Ziglio, Marco Montalti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Healthcare |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9032/11/7/1013 |
Similar Items
-
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
by: David Adams, et al.
Published: (2017-09-01) -
Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
by: Luca Gentile, et al.
Published: (2021-04-01) -
Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
by: Dixon S, et al.
Published: (2023-11-01) -
Phenotypic heterogeneity and diagnostic features of transthyretin amyloidosis with polyneuropathy
by: S. S. Nikitin, et al.
Published: (2021-12-01) -
«Red flags» en pacientes con polineuropatía amiloidótica familiar relacionada con transtiretina (hATTR) en el momento del diagnóstico en un área no endémica de España
by: L. Silva-Hernández, et al.
Published: (2023-03-01)